To attend, please ensure you are registered for the ASBMR annual meeting.
Osteogenesis imperfecta (OI), or brittle bone disease, is an uncommon genetic disorder characterized by shortness of stature, hearing loss, poor bone mass, recurrent fractures, and skeletal abnormalities. Pathogenic variations have been found in several distinct genes that are involved in the pathophysiology of OI, contributing to the disorder's clinical and genetic variability. Although medications, surgical procedures, and other interventions can partially alleviate certain symptoms, the clinical trial data of a recent FDA breakthrough therapy designation for OI has been shown to provide meaningful improvements in lumbar spine bone mineral density.
Join us for this live symposium as we present a comprehensive review of the classifications, characteristics, causes, symptoms, and prognosis of patients with OI through expert-led discussions, case-based presentations, and a question-and-answer session. Clinically relevant data results of the latest breakthrough therapy in OI, with a potential to positively impact patient outcomes, will be discussed.
Schedule |
|
| * Times are PST | |
| 06:00 AM | Registration and Breakfast Buffet |
| 06:15 AM | Welcome, Disclosures, Supporter Acknowledgement |
| 06:20 AM |
Presentation
Osteogenesis Phenotypes / Classifications |
| 07:30 AM | Closing Comments, Audience Q&A |
| 07:45 AM | Adjourn |
V. Reid Sutton, MD
Professor, Department of Molecular & Human Genetics
Baylor College of Medicine & Texas Children's Hospital
Medical Director, Biochemical Genetics
Baylor Genetics - Houston, TX
Member of the Brittle Bone Disorders Consortium
Gary Gottesman, MD
Director, Pediatric Bone Disorder Program
Professor of Pediatrics and Medicine
John T. Milliken Department of Medicine
Division of Bone and Mineral Diseases
Washington University School of Medicine
St. Louis, MO
Kathryn M. Dahir, MD
Director, Program for Metabolic Bone Disorders
Professor of Medicine
Division of Diabetes and Endocrinology
Vanderbilt Center for Bone Biology
Department of Medicine and Division of Clinical Pharmacology
Nashville, TN
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Canadian CME: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
The UEMS-EACCME®: The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement, the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live and enduring activities certified by the AMA.
Physician Assistants and Nurse Practitioners: The National Commission on Certification of Physician Assistants (NCCPA) and the American Academy of Nurse Practitioners (AANP) accept AMA PRA Category 1 Credit™ from organizations accredited by ACCME through its reciprocity agreements.
- Identify the different newly named classifications of OI based on phenotypic characteristics and mode of inheritance
- Discuss the causes, symptoms, and prognosis of pediatric and adult patients with OI using sample patient cases
- Assess existing medical and orthopedic management strategies for treatment
- Review clinical data results: Latest breakthrough therapy designation